Cingulate

Cingulate EBIT Growth

The Year-over-Year EBIT Growth of Cingulate (CING) as of Oct 22, 2026 is -34.80 %. In the previous year, Year-over-Year EBIT Growth was 31.28 % — a change of -211.23% (lower).

EBIT Growth

-34.80 %

YoY

-211.23%

Last updated:

Year-over-Year EBIT Growth of Cingulate is 2025 -34.80 % . Year-over-Year EBIT Growth of Cingulate was 2024 31.28 % . It decreases by -211.23% lower compared to the previous year.

The Cingulate EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2020
39.18 USD
Jan 1, 2021
-191.94 USD
Jan 1, 2022
15.37 USD
Jan 1, 2023
-30.08 USD
Jan 1, 2024
31.28 USD
Jan 1, 2025
-34.80 USD
The Cingulate EBIT Growth history
YEAREBIT GrowthYoY
-34.80 %-211.23%
31.28 %-203.98%
-30.08 %-295.77%
15.37 %-108.01%
-191.94 %-589.85%
39.18 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cingulate Stock analysis

What does Cingulate do? Cingulate Inc is a US-based biopharmaceutical company headquartered in Kansas City, Kansas, that focuses on the development, manufacturing, and commercialization of pharmaceutical products. The firm utilizes its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles designed to improve the lives of patients suffering from commonly diagnosed conditions. The company specifically targets the treatment of attention deficit/hyperactivity disorder (ADHD) through its innovative approach to drug delivery. The firm is currently developing two lead product candidates, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). These drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. By employing this technology, Cingulate Inc aims to provide effective treatment options for ADHD across three core patient segments: children aged 6-12, adolescents aged 13-17, and adults aged 18 and older. Cingulate is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cingulate stock

Year-over-Year EBIT Growth of Cingulate is -34.80 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Cingulate since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Cingulate historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Cingulate

All Key Metrics — Cingulate